BACKGROUND: The Kidney Disease: Improving Global Outcomes (KDIGO) system for classification of acute kidney injury (AKI) severity utilizes a staging schema based on relative changes in serum creatinine (sCr) concentration and urine output. This study compares the in-hospital mortality associated with KDIGO-defined AKI stages and AKI stages defined by absolute sCr increases ('Delta-Creatinine'). METHODS: The study included an analysis of hospital discharge and laboratory data from an urban academic medical center over a 1-year period. Including adult in-patients undergoing two or more sCr measurements, the study classified AKI stages using the KDIGO consensus standards as well as absolute increases in sCr ('Delta-Creatinine'); Stage 0, sCr increase <0.3 mg/dL, Stage 1, sCr increase 0.3-0.69 mg/dL, Stage 2, sCr increase 0.7-1.19 mg/dL and Stage 3, sCr increase ≥1.2 mg/dL or initiation of renal replacement therapy. The Delta-Creatinine cut-points were defined to optimize discrimination of in-patient mortality between AKI stages. The associations between KDIGO and Delta-Creatinine AKI stages and in-hospital mortality were compared using the time-dependent hazard ratios (HRs) and the net reclassification improvement (NRI). RESULTS: Of the 19 878 hospitalizations included in the analysis, the prevalence of AKI was 23.4% as defined by the KDIGO criteria. The Delta-Creatinine system discriminated the differences between adjacent AKI stages (i.e. 1 versus 0, 2 versus 1, 3 versus 3) earlier than the KDIGO system. The NRI between Delta-Creatinine and KDIGO for the prediction of mortality was 9.7% [95% confidence interval (CI) 6.2-13.2%]. Stratification by age, sex, race and history of chronic kidney disease (CKD) resulted in similar NRI values. CONCLUSION: The Delta-Creatinine system, based on the absolute increases in sCr, provides a promising alternative to the KDIGO system for characterizing the severity of AKI and its associations with in-patient mortality.
BACKGROUND: The Kidney Disease: Improving Global Outcomes (KDIGO) system for classification of acute kidney injury (AKI) severity utilizes a staging schema based on relative changes in serum creatinine (sCr) concentration and urine output. This study compares the in-hospital mortality associated with KDIGO-defined AKI stages and AKI stages defined by absolute sCr increases ('Delta-Creatinine'). METHODS: The study included an analysis of hospital discharge and laboratory data from an urban academic medical center over a 1-year period. Including adult in-patients undergoing two or more sCr measurements, the study classified AKI stages using the KDIGO consensus standards as well as absolute increases in sCr ('Delta-Creatinine'); Stage 0, sCr increase <0.3 mg/dL, Stage 1, sCr increase 0.3-0.69 mg/dL, Stage 2, sCr increase 0.7-1.19 mg/dL and Stage 3, sCr increase ≥1.2 mg/dL or initiation of renal replacement therapy. The Delta-Creatinine cut-points were defined to optimize discrimination of in-patient mortality between AKI stages. The associations between KDIGO and Delta-Creatinine AKI stages and in-hospital mortality were compared using the time-dependent hazard ratios (HRs) and the net reclassification improvement (NRI). RESULTS: Of the 19 878 hospitalizations included in the analysis, the prevalence of AKI was 23.4% as defined by the KDIGO criteria. The Delta-Creatinine system discriminated the differences between adjacent AKI stages (i.e. 1 versus 0, 2 versus 1, 3 versus 3) earlier than the KDIGO system. The NRI between Delta-Creatinine and KDIGO for the prediction of mortality was 9.7% [95% confidence interval (CI) 6.2-13.2%]. Stratification by age, sex, race and history of chronic kidney disease (CKD) resulted in similar NRI values. CONCLUSION: The Delta-Creatinine system, based on the absolute increases in sCr, provides a promising alternative to the KDIGO system for characterizing the severity of AKI and its associations with in-patient mortality.
Authors: Alina M Robert; Robert S Kramer; Lawrence J Dacey; David C Charlesworth; Bruce J Leavitt; Robert E Helm; Felix Hernandez; Gerald L Sardella; Carmine Frumiento; Donald S Likosky; Jeremiah R Brown Journal: Ann Thorac Surg Date: 2010-12 Impact factor: 4.330
Authors: Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates Journal: J Am Soc Nephrol Date: 2005-09-21 Impact factor: 10.121
Authors: Britt B Newsome; David G Warnock; William M McClellan; Charles A Herzog; Catarina I Kiefe; Paul W Eggers; Jeroan J Allison Journal: Arch Intern Med Date: 2008-03-24
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Scott M Sutherland; John J Byrnes; Manish Kothari; Christopher A Longhurst; Sanjeev Dutta; Pablo Garcia; Stuart L Goldstein Journal: Clin J Am Soc Nephrol Date: 2015-02-03 Impact factor: 8.237
Authors: Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Guadalupe Garcia-Tsao; Patrick S Kamath; Scott W Biggins; Michael B Fallon; Ram M Subramanian; B Maliakkal; Leroy Thacker; Jasmohan S Bajaj Journal: Dig Dis Sci Date: 2016-12-26 Impact factor: 3.199
Authors: Martin Christ; Katharina Isabel Auenmüller; Scharbanu Amirie; Michael Brand; Benjamin Michel Sasko; Hans-Joachim Trappe Journal: Herzschrittmacherther Elektrophysiol Date: 2015-12-15
Authors: Francisco Ribeiro-Mourão; Ana Carvalho Vaz; André Azevedo; Helena Pinto; Marta João Silva; Joana Jardim; Augusto Ribeiro Journal: Pediatr Nephrol Date: 2021-06-08 Impact factor: 3.714